Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference
04 avr. 2023 10h43 HE | Tiziana Life Sciences Ltd.
Dr. Saef Izzy’s data shows one-month behavioral outcomes improvement in model of intracerebral hemorrhage (hemorrhagic stroke)Modulation of neuroinflammation by inducing FoxP3+ Tregs appears to have...
Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage
04 avr. 2023 07h00 HE | Tiziana Life Sciences Ltd.
Tiziana planning to advance foralumab, the only fully human anti-CD3 monoclonal antibody, into human testing for hemorrhagic strokeData shows behavioral outcomes improvement at one month in model of...
NovaSignal Logo.png
NovaSignal Donates NovaGuide™ 2 Intelligent Ultrasound to The Jacobs Institute to Advance Stroke Research
28 févr. 2023 09h03 HE | NovaSignal Corporation
LOS ANGELES, Feb. 28, 2023 (GLOBE NEWSWIRE) -- NovaSignal Corp., a medical technology and data company specializing in the assessment and management of brain health, today announced the donation of...
formable™ Establishes Platform of World-Renowned Coaches Offering Swim and Run Form Analyses to Maximize Performance and Reduce Injury Among Athletes
18 janv. 2023 09h00 HE | formable
GLEN ROCK, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Endurance sports company, AgeGrouper, launches formable™, a dedicated platform that connects athletes with coaches to provide virtual run and swim...
Anthos Logo Transparent.png
First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients with Atrial Fibrillation Deemed Unsuitable for Current Anticoagulants
03 janv. 2023 08h00 HE | Anthos Therapeutics
FDA Fast-Track designation was granted to investigate abelacimab for the prevention of stroke and systemic embolism in patients with atrial fibrillation LILAC-TIMI 76 trial is the third Phase 3...
Global Atrial Fibrillation Treatment Market
Outlook on the Atrial Fibrillation Treatment Global Market to 2027 - Rising Prevalence of Cardiovascular Diseases Drives Growth
22 déc. 2022 06h38 HE | Research and Markets
Dublin, Dec. 22, 2022 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
Persistence Market Research
Induced Pluripotent Stem Cells Production Market is expected to reach US$ 2.9 Bn By 2032 at a CAGR of 10.7% | According to PMR
20 déc. 2022 08h30 HE | Persistence Market Research
New York, Dec. 20, 2022 (GLOBE NEWSWIRE) -- The Induced Pluripotent Stem Cells Production market revenues were estimated at US$ 949.6 Mn in 2021 and is anticipated to grow at a CAGR of 10.7% from...
$55+ Billion Stroke Management Market Size to Rise at a Stellar CAGR of 7.5% During (2022-2028) - COVID-19 Impact and Global Analysis by The Insight Partners
18 oct. 2022 08h40 HE | The Insight Partners
New York, Oct. 18, 2022 (GLOBE NEWSWIRE) -- According to The Insight Partners latest market study on "Stroke Management Market Size, Share, Trends, Growth Strategy and Forecast to 2028 – COVID-19...
GNT Logo.png
GNT Pharma Provides Update on Two Phase III Studies of Nelonemdaz for Acute Ischemic Stroke Patients Treated with tPA (ENIS-3) or Endovascular Thrombectomy (RODIN)
19 sept. 2022 09h00 HE | GNT Pharma Co., Ltd
Promising efficacy and safety profiles were observed in prior Phase II studies in acute ischemic stroke patients treated with recanalization therapies. The ENIS-3 trial has achieved >33% of...
Algernon Logo 1.png
Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study
12 sept. 2022 07h00 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage...